Cercar
22/02/2023
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis, G, Warren, RB, Strober, B, Blauvelt, A, Puig, L, Morita, A, Gooderham, M, Korber, A, Vanvoorden, V, Wang, M, de Cuyper, D, Madden, C, Gomez, NN, Lebwohl, M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(3)DOI:10.1093/bjd/ljac089. PMID:36751950. IF:11.000(Q1/1D).
20/02/2023
Effectiveness of four deconstructive meditative practices on well-being and self-deconstruction: study protocol for an exploratory randomized controlled trial
García-Campayo J., Hijar-Aguinaga R., López-Del-Hoyo Y., Magallón-Botaya R., Fernández-Martínez S., Barceló-Soler A., Soler-Ribaudi J., Montero-Marin J.. Effectiveness of four deconstructive meditative practices on well-being and self-deconstruction: study protocol for an exploratory randomized controlled trial. Trials. 2023; 24(1)DOI:10.1186/s13063-023-07151-0. PMID:36805694. IF:2.000(Q3/7D).
20/02/2023
Expanded hemodialysis: what's up, Doc?
Garcia-Prieto, A, de la Flor, JC, Coll, E, Iglesias, E, Reque, J, Valga, F. Expanded hemodialysis: what's up, Doc?. Clinical Kidney Journal. 2023; 16(7)DOI:10.1093/ckj/sfad033. PMID:37398691. IF:3.900(Q1/2D).
19/02/2023
Soluble low-density lipoprotein receptor-related protein 1 as a surrogate marker of carotid plaque inflammation assessed by 18F-FDG PET in patients with a recent ischemic stroke
Garcia E., Camps-Renom P., Puig N., Fernández-Leon A., Aguilera-Simón A., Benitez-Amaro A., Solé A., Vilades D., Sanchez-Quesada J.L., Martí-Fàbregas J., Jiménez-Xarrié E., Benitez S., Llorente-Cortés V.. Soluble low-density lipoprotein receptor-related protein 1 as a surrogate marker of carotid plaque inflammation assessed by 18F-FDG PET in patients with a recent ischemic stroke. Journal of Translational Medicine. 2023; 21(1)DOI:10.1186/s12967-022-03867-w. PMID:36805772. IF:6.100(Q1/2D).